HUVECisolatedinEGM™-PlusGrowthMedium(underlightmicroscopy)
New! HUVECsculturedinEGM™-Plus GrowthMediaofferfasterproliferationrateswhilemaintainingthesamehighqualitycharacterizationasHUVECsinEGM™Media | Interestedtolearnmore? Requestinfoorquote | |
| NotAllHUVECsAreCreatedEqual–Which TypeIs SuitableforYourResearch? |
| HUVECType | CatalogNumber | Characteristics |
|---|---|---|
| IsolatedinEGM™Media | CC-2517(singledonor),CC-2519(pooleddonor) | Isolatedinabsenceofdefinedgrowthfactors.ContainsBBE.NoexogenousVEGF |
| New!IsolatedinEGM™-PlusMedia | CC-2935(singledonor) | ImprovedversionofpartnumberCC-2517.OffersfasterproliferationratesthanHUVECisolatedinEGM™GrowthMedia.NoexogenousVEGF |
| IsolatedinEGM™-2Media | C2517A(singledonor),C2519A(pooleddonor)00191027(XLsize) | IsolatedinpresenceofgrowthfactorssuchasVEGF,rhFGF,rhEGF,andothers. DoesnotcontainBBE |
| Pre-screenedHUVECsinEGM™-2Media | C2517AS(singledonor),C2519AS(pooleddonor) | ScreenedforangiogenesisMarkersandtestpositiveforexpressionofeNOS,Axl,Tie-2andVEGFr2 |
| ProductSpecifications:
Lonza"sCryopreserved HUVECsareshippedasfrozenprimaries. Theyareguaranteedthrough15*populationdoublings(*exceptHUVEC-XL™guaranteedthrough5PD),expressCD31/105,vonWillebrandFactorVIII,andarepositiveforacetyatedlowdensitylipoproteinuptake.Allcells testnegativeformycoplasma,bacteria,yeast,andfungi.HIV-1,hepatitisBandhepatitisCarenotdetectedforalldonorsand/orcelllots.ACertificateofAnalysisisprovidedforeachcelllotpurchased.
Ourpooledvs.singledonoroptionsallowresearcherstostudyorexcludedonorvariABIlityfromtheirexperiments. Dependinguponthestudy,pooledversionistypicallyutilizedtoreducedonorvariabilitywhilesingledonoroptionallowsresearcherstoassessdonor-specificdifferences.
HUVEC-XLsizeconsistsof10millioncells/ampachievedbypoolingdonors.Thisoptionisdesignedtosupportstudiesthatrequirelargevolumeofcellswhilestillofferingcost-benefitstoresearchers.
MostLonzaPrimaryCellsarealsoavailableas proliferatingcellsineitherflasksorplates,oraspelletsinRNALater®.
Recommendedmedium:EGM™,EGM™-PlusandEGM™-2BulletKits™,seeaboveforcat.no.specificallyoptimizedwitheachkit |
| WhitePapers–Learnmore | ||
 |
| |
| Registertodownload | ||
龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach，公司经营范围包括：生物技术开发服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术推广服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术咨询、交流服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术转让服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;医学研究和试验发展（人体干细胞、基因诊断与治疗技术除外）;药品研发（人体干细胞、基因诊断与治疗技术除外）;货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易（涉及外资准入特别管理规定和许可审批的商品除外）;生物药品制造;化学药品原料药制造;化学药品制剂制造等。
本网站将在规定时间内给予删除等相关处理。
